Clinical trial
Combination Chemo, Peripheral Stem Cell Transplant, Biological Therapy…
NCT00004088 · City of Hope Medical Center, Other · Completed
Key facts
| NCT number | NCT00004088 |
|---|---|
| Title | Combination Chemo, Peripheral Stem Cell Transplant, Biological Therapy, Pamidronate and Thalidomide for Multiple Myeloma |
| Official title | Sequential High-Dose Melphalan and Busulfan/Cyclophosphamide Followed by Peripheral Blood Progenitor Cell Rescue, Interferon/Thalidomide and Pamidronate for Patients With Multiple Myeloma |
| Lead sponsor | City of Hope Medical Center, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Multiple Myeloma and Plasma Cell Neoplasm |
| Intervention type | Biological, Drug, Procedure |
| Interventions | filgrastim, recombinant interferon alfa, busulfan, cyclophosphamide, melphalan, pamidronate disodium, thalidomide, peripheral blood stem cell transplantation |
| Enrollment | 77 |
| Start date | Apr 13, 1999 |
| Primary completion | Jan 9, 2018 |
| Completion | Jan 9, 2018 |
| First posted | Jan 27, 2003 |
| Last update posted | Jul 2, 2019 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: